Lanean...
Nilotinib-Induced Keratosis Pilaris
Nilotinib is a second-generation Bcr-Abl tyrosine kinase inhibitor (TKI) that is approved for the treatment of imatinib-resistant chronic myeloid leukaemia expressing the Bcr-Abl mutation. Cutaneous adverse drug reactions occur more frequently in patients using this medication. We present a case of...
Gorde:
| Argitaratua izan da: | Case Rep Dermatol |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
S. Karger AG
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4868941/ https://ncbi.nlm.nih.gov/pubmed/27194977 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000445676 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|